Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Clinical trial NCT07334431 · RECRUITING
Trial details
- NCT number
- NCT07334431
- Sponsor
- Henan Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-22
- Primary completion
- 2025-12-31
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.